Liestal, Switzerland, September 12, 2011 - Santhera Pharmaceuticals (SIX: SANN) today announced that Klaus Schollmeier, Chief Executive Officer, will sit on an expert panel on Public Markets & M&A Finance at the upcoming 11th Annual Biotech in Europe Investor Forum in Zurich, Switzerland. The panel will be held on Tuesday, September 13, 2011 at 10.00 CET. Later in the day, Mr Schollmeier will give a company presentation at 15:15 CET. The international investor conference is being held on September 13 and 14, 2011 at the Hilton Zurich Airport.
About Sachs Biotech in Europe Investor Forum
The Annual Biotech in Europe Investor Forum is an exclusive and highly transactional forum for investing and partnering in the Biotech and Pharma industry. With over 70 presenting companies and plenary panel sessions from experts in their sector, the forum provides opportunities to gain insight into partnering and investment trends in the Biotech and Pharma industry. Up to 400 delegates and 150 companies are expected at the two-day conference.
* * *
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of severe neuromuscular diseases, an area of high unmet medical need which includes many orphan indications with no current therapy. Santhera's first product, Catena®, to treat Friedreich's Ataxia is marketed in Canada. Catena® is currently under review for marketing authorization by the European Medicine Agency as the first therapy for patients suffering from Leber's Hereditary Optic Neuropathy. For further information, please visit www.santhera.com.
Catena® is a trademark of Santhera Pharmaceuticals.
For further information, contact
Thomas Staffelbach, Head Public & Investor Relations
Phone: +41 (0)61 906 89 47
thomas.staffelbach@santhera.com
Disclaimer/Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.